These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 24573776)

  • 1. Prospects for neuroprotective therapies in prodromal Huntington's disease.
    Chandra A; Johri A; Beal MF
    Mov Disord; 2014 Mar; 29(3):285-93. PubMed ID: 24573776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.
    Naia L; Ribeiro MJ; Rego AC
    Rev Neurosci; 2011 Dec; 23(1):13-28. PubMed ID: 22150069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington's disease-like behavioral, biochemical, and cellular alterations: Restoration of coenzyme-Q10-mediated mitochondrial dysfunction.
    Mehan S; Monga V; Rani M; Dudi R; Ghimire K
    Indian J Pharmacol; 2018; 50(6):309-319. PubMed ID: 30783323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.
    Joshi AU; Ebert AE; Haileselassie B; Mochly-Rosen D
    J Mol Cell Cardiol; 2019 Feb; 127():125-133. PubMed ID: 30550751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidants in Huntington's disease.
    Johri A; Beal MF
    Biochim Biophys Acta; 2012 May; 1822(5):664-74. PubMed ID: 22138129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Huntington's disease].
    Rollnik JD
    Nervenarzt; 2015 Jun; 86(6):725-35. PubMed ID: 25940443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies.
    Wright GEB; Black HF; Collins JA; Gall-Duncan T; Caron NS; Pearson CE; Hayden MR
    Lancet Neurol; 2020 Nov; 19(11):930-939. PubMed ID: 33098802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.
    Essa MM; Moghadas M; Ba-Omar T; Walid Qoronfleh M; Guillemin GJ; Manivasagam T; Justin-Thenmozhi A; Ray B; Bhat A; Chidambaram SB; Fernandes AJ; Song BJ; Akbar M
    Neurotox Res; 2019 Apr; 35(3):739-774. PubMed ID: 30632085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington's disease.
    Shafie A; Ashour AA; Anwar S; Anjum F; Hassan MI
    Arch Pharm Res; 2024 Jun; 47(6):571-595. PubMed ID: 38764004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of gene editing for Huntington's disease.
    Duan W; Urani E; Mattson MP
    Trends Neurosci; 2023 May; 46(5):365-376. PubMed ID: 36907678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
    McBride JL; Ramaswamy S; Gasmi M; Bartus RT; Herzog CD; Brandon EP; Zhou L; Pitzer MR; Berry-Kravis EM; Kordower JH
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9345-50. PubMed ID: 16751280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Huntington's disease: a clinical review.
    McColgan P; Tabrizi SJ
    Eur J Neurol; 2018 Jan; 25(1):24-34. PubMed ID: 28817209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
    Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
    Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
    Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
    Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease: an update of therapeutic strategies.
    Kumar A; Kumar Singh S; Kumar V; Kumar D; Agarwal S; Rana MK
    Gene; 2015 Feb; 556(2):91-7. PubMed ID: 25447911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease: pathological mechanisms and therapeutic strategies.
    Ramaswamy S; Shannon KM; Kordower JH
    Cell Transplant; 2007; 16(3):301-12. PubMed ID: 17503740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease.
    Tobore TO
    J Neurosci Res; 2019 Nov; 97(11):1455-1468. PubMed ID: 31304621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.